



Zentrum für Klinische Studien · Frondsbergstraße 23 · 72070 Tübingen

Medizinische Fakultät

ZKS Tübingen
Zentrum für Klinische Studien

Prof. Dr. Wolfgang Bethge
Leitung

Telefon +49 7071 29-85635
Telefax +49 7071 29-25080
wolfgang.bethge@med.uni-tuebingen.de
www.zks-tuebingen.de



Tübingen, 05.11.2020

Prematurely ended -statement

EudraCT number: 2011-002192-41

Full title of the study: Multicenter phase II study of peritransplantation immunosuppression using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with Fludarabine and Treosulfan

Study Contact: Prof. Dr. Wolfgang Bethge

Sponsor: University Hospital Tübingen

Contact email address: wolfgang.bethge@med.uni-tuebingen.de


Product:

- Grafalon ®: Anti-humane-T-lymphocyte immunoglobiline (ATG)
- Rapamune ®: Sirolimus
- CellCept®: Mycophenolate Mofetil
- Mabthera® Rituximab

Date of the early termination of the trial: 17.08.2016

Statement on discontinuation of the study: Study prematurely ended due to poor recruitment. 30 patients was planned to be included in this protocol, a total of nine patients have been enrolled into the study prior to the pre-termination.

Signature


Job role: Head of Center for Clinical Trials